NCT07466420 Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
| NCT ID | NCT07466420 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Katerina M. Antoniou |
| Condition | Fibrotic Interstitial Lungs Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-01-26 |
| Primary Completion | 2028-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-01-26 with a primary completion date of 2028-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung function, respiratory failure, and high mortality, despite the currently approved antifibrotic treatment. While its exact cause remains unknown, pulmonary fibrosis is strongly linked to aging, genetic predisposition, environmental factors, and cellular senescence. Ongoing research aims to identify reliable biomarkers and develop targeted treatments to enhance patient outcomes. This randomized controlled trial will examine the effects of quercetin supplementation (500 mg/day for two 12-week cycles, with one 8-week washout periods) on telomere length, senescence-associated secretory phenotype (SASP) factors, and lung function in patients with IPF and F-ILDs. A total of 100 patients will be recruited, with half receiving quercetin (despite their standard of care therapy) and the other half receiving standard care (SOC). Primary outcomes will include changes in telomere length, SASP protein levels (IL-6, MMPs), fractional exhaled nitric oxide (FeNO), spirometry (FVC decline), and oscillometry measurements. Additionally, quality of life will be assessed using the L-IPF Questionnaire. This study aims to explore quercetin's potential to reduce fibrosis, decrease inflammation, and improve lung function in F-ILDs, offering new insights into potential novel strategies for F-ILD management.
Eligibility Criteria
Inclusion Criteria: * Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study. * The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as standard of care. Exclusion Criteria: * Subjects with a result of FeNO\>25 ppb will be excluded from the study to ensure that no other pulmonary diseases, such as asthma, are present. * Patients who do not initiate quercetin within the first week after their baseline visit.
Contact & Investigator
Katerina M. Antoniou, MD PhD, Professor
PRINCIPAL INVESTIGATOR
Department of Respiratory Medicine, University Hospital of Heraklion, School of Medicine, University of Crete
Frequently Asked Questions
Who can join the NCT07466420 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Fibrotic Interstitial Lungs Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07466420 currently recruiting?
Yes, NCT07466420 is actively recruiting participants. Contact the research team at ioannaar07@gmail.com for enrollment information.
Where is the NCT07466420 trial being conducted?
This trial is being conducted at Heraklion, Greece.
Who is sponsoring the NCT07466420 clinical trial?
NCT07466420 is sponsored by Katerina M. Antoniou. The principal investigator is Katerina M. Antoniou, MD PhD, Professor at Department of Respiratory Medicine, University Hospital of Heraklion, School of Medicine, University of Crete. The trial plans to enroll 100 participants.